Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2014

Basis of Presentation and Summary of Significant Accounting Policies

Analysis of U.S. Feraheme product sales allowances and accruals

An analysis of our U.S. Feraheme product sales allowances and accruals for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

	Three Months Ended March 31,
	2014			2013
Provision for U.S. Feraheme product sales allowances and accruals
Discounts and chargebacks	$	10,533		$	7,493
Government and other rebates	3,187			2,387
Returns	226			193
Total provision for U.S. Feraheme product sales allowances and accruals	$	13,946		$	10,073
Total gross U.S. Feraheme product sales	$	31,321		$	25,651
Total provision for U.S. Feraheme product sales allowances and  accruals as a percent of total gross U.S. Feraheme product sales	45		%	39		%

Schedule of customers representing 10% or more of revenues

	Three Months Ended March 31,
	2014		2013
AmerisourceBergen Drug Corporation	39	%	43	%
McKesson Corporation	22	%	22	%
Cardinal Health, Inc.	15	%	15	%
Takeda Pharmaceuticals Company Limited	11	%	12	%